Chemotherapy for colorectal cancer

Midgley R , Kerr D. Colorectal cancer. Lancet 1999; 353: 391–9

The Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomised trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960–9

Anonymous. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (in press)

Pazdur R , Douillard J-Y , Skillings JR Multicentre phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1009

Twelves C , Harper P , Van Cutsem E. A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1010

Carmichael J , Popiela T , Radstone D Randomised comparative study of ORZEL (oral uracil/Tegafur) plus leucovorin (IV) versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1015

Cox JV , Pazdur R , Thibault A A phase II trial of Xeloda TM (capecitabine) in previously untreated advanced/metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1016

Meta-analysis Group in Cancer. Re-appraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252–8

Kemeny MM , Cohen A , Huang Y Randomised study of hepatic arterial infusion and systemic versus systemic alone as adjuvant therapy after resection of hepatic metastases from colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1011

Kemeny MM , Adak S , Gray B Results of the Intergroup (Eastern Co-operative Group (ECOG) and Southwest Oncology Group (SWOG) prospective randomised study of surgery alone versus continuous hepatic arterial infusion of FudR and continuous infusion of 5-fluorouracil after hepatic resection for colorectal liver metastases [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1012

Maughan TS , James RD , Kerr D On behalf of the British MRC Colorectal Cancer Working Party. Preliminary results of a multicentre randomised trial comparing three chemotherapy regimens (de Gramont, Lokich, and Ralitrexed) in metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 1007

Cunningham D , Pyrhonen S , James RD Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–18

Saltz L , Locker P , Pirotta N Weekly irinotecan, leucovorin and fluorouracils superior to daily x 5 LV/FU in patients with previously untreated metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 898

De Gramont A , Vignoud J , Tournigant C Oxaliplatin with high dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 32: 214–19

Moertel CG , Fleming TH , MacDonald JS Levamisole and fluorouracil for adjuvant treatment of resected colon cancer. N Engl J Med 1990; 322: 352–8

Midgley RS , Kerr DJ. Adjuvant treatment of colorectal cancer. Cancer Treatment Rev 1997; 23: 135–52

QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet 2000; 355: 1588–96

Liver infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer; a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 89: 497–505

Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136–43

Riethmuller G , Schneider-Gadicke E , Schmilok G. Randomised trial of monoclonal antibody for adjuvant treatment of resected Dukes C colorectal cancer. Lancet 1994; 343: 1177–83

Huber BE , Austin EA , Good SS In vivo anti-tumour activity of 5-fluorouracil on human CRC cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619–26